Activated monocytes play an important role in the pathogenesis of inflammatory arthritis. Blood monocytes which enter the inflamed joint become activated upon adherence to extracellular matrix and exposure to a complex inflammatory environment. We have analyzed the mechanism of monocyte activation by soluble factors present in inflammatory synovial fluid (SF). Greater than 75 % of inflammatory SFs tested (a total of 22 fluids to date) increased cell surface expression and dramatically increased mRNA levels of monocyte activation markers Fc'yRI, Fc'yRIII, and HLA-DRA. This induction was not triggered by adherence, a known activating stimulus, and several lines of evidence showed that induction was not dependent upon interferon 3' (IFN-3,). Induction was not prevented by neutralizing anti-IFN-3, antibodies and IFN-3~ was not detected in the SFs using a sensitive enzyme-linked immunosorbent assay. The SFs also were not able to activate the IFN-3,-activated transcription factor Statl, thus providing further support for the absence of IFN-'y. SFs did activate a related signal transducer and activator of transcription (STAT) family factor, termed Stat-SF, which bound specifically to the IFN-'y response region (GRR), a well-characterized transcription element in the Fc'yRI promoter. Based upon DNAbinding specificity and mobilities in gel shift assays, and reactivity with specific antisera, Stat-SF likely contains Stat3, or a closely related STAT family member. Neutralization of interleukin 6, a cytokine present in SFs which is known to activate Stat3, abolished the activation of Stat-SF and inhibited the induction of Fc3'RI expression by SFs. These results demonstrate the activation of monocytes by inflammatory SF and suggest that monocyte activation at an inflammatory site may occur in the absence of IFN-'y through the triggering of signal transduction pathways that activate STAT transcription factors. ctivated monocytes are found in the inflamed synovium of patients with inflammatory arthritis, such as rheumatoid arthritis (RA) I. These monocytes express high levels of immune effector molecules such as HLA class II antigens, Fc receptors (FcR), proteases, cytokines, and chemotactic factors (1-15 and references therein). Activated monocytes may contribute to the pathogenesis of inflammatory arthritis through several mechanisms, including increased (auto)antigen presentation by class II molecules, increased cytotoxicity and release of toxic reactive oxygen intermediates mediated by FcR, degradation of connective tissue by proteases,
ctivated monocytes are found in the inflamed synovium of patients with inflammatory arthritis, such as rheumatoid arthritis (RA) I. These monocytes express high levels of immune effector molecules such as HLA class II antigens, Fc receptors (FcR), proteases, cytokines, and chemotactic factors (1-15 and references therein). Activated monocytes may contribute to the pathogenesis of inflammatory arthritis through several mechanisms, including increased (auto)antigen presentation by class II molecules, increased cytotoxicity and release of toxic reactive oxygen intermediates mediated by FcR, degradation of connective tissue by proteases, 1 Abbreviations used in this paper: EU, endotoxin unit; GRR, IFN-"/response region; OA, osteoarthritis; PDGF, platelet-derived growth factor; RA, rheumatoid arthritis; SF, synovial fluid; STAT, signal transducer and activator of transcription. stimulation of inflammation by secretion ofproinflammatory cytokines, and recruitment of new inflammatory cells to the joint by secreted chemotaxins.
Multiple pro-inflammatory mediators have been measured in the inflamed joint (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) , but the identity of the major monocyte activator(s) in vivo has not been conclusively demonstrated. IFN-% a potent monocyte activator which can activate many complex effector functions, has been proposed to activate monocytes in inflammatory arthritis. The role of IFN-y, however, is controversial because it has been difficult to detect IFN-3, in synovial fluid (SF) specimens (1-4, 6, 9, 13, 14) , and indeed, one group has suggested that IFN-3/ synthesis is actively suppressed during synovitis (9) . Other factors which have been detected in the inflamed joints of patients, such as IL-1, Ib6, II.-8, TNF-c~, platelet-derived growth factor (PDGF), GM-CSF, and complement breakdown products, have been postulated to be important in driving monocyte activation and synovial inflammation. However, it is unclear whether these factors are present in a bioactive form (9, 16) . Furthermore, since the biological effect of a cytokine can be altered or even switched to have the completely opposite effect in the presence of other stimuli (16) (17) (18) , it is difficult to predict the role of a cytokine in vivo based upon studies with individual purified cytokines in vitro.
Monocyte activation is a complex process that can be triggered by multiple stimuli, which often act in concert (19) . Since different stimuli can trigger different effector functions, the functional characteristics of the activated monocyte can vary. IFN-3~ and bacterial endotoxin are the most potent monocyte-activating factors, and are capable of activating complex effector functions such as antigen presentation and cytotoxicity. Other stimuli, such as the cytokines II:1, IL-6, TNF-o6 and GM-CSF, or adherence to extracellular matrix, have been shown to induce monocyte "early genes" or other cytokine genes. The effect of these stimuli upon monocyte phenotype or effector functions has not been as well characterized as the effect of IFN-% but they appear to trigger a more limited cellular response (19, 20) . Thus, activation of monocyte effector functions in the absence of IFN-3/or endotoxin may depend upon the concerted action of several activating stimuli.
A large number of cytokines, growth factors, and the IFNs have been shown to activate the JAK family of tyrosine kinases, which phosphorylate and activate the STAT (signal transducers and activators of transcription) transcription factors (21) . To date, five distinct but homologous members of the STAT family have been identified and designated Star1 through Stat5. STAT proteins are localized to the cytoplasm or the plasma membrane in resting cells. After activation, the STATs dimerize, translocate to the nucleus, and acquire DNA-binding activity. An individual STAT protein may be activated by multiple ligands, but certain ligands preferentially activate particular STATs (21) . For example, IFN-'r preferentially activates Statl (previously designated IFN-y activated factor [GAF], p91, or Stat91), and I1:6 preferentially activates Stat3. Stat3, which is contained in complexes that have been termed serum induced factor A (SIF-A) or acute phase response factor (APRF) (22) (23) (24) , is activated by several stimuli which have been detected in inflammatory SFs, including I1:6, I1:10, IFN-o6 PDGF, and leukemia inhibitory factor (LIF) (21) (22) (23) (24) .
We have chosen to study the response of monocytes to a complex inflammatory environment that attempts to reproduce in vivo conditions, rather than the response to purified cytokines. In our experiments, we have modeled the in vivo process of monocyte migration into an inflamed joint by simultaneously adhering purified human blood monocytes to a substrate and exposing them directly to SF. A majority of the SF samples induced several monocyte activation markers such as FcR and HLA DR antigens. This induction appears to be independent of IFN-y but does involve the triggering of a signal transduction pathway that activates a STAT transcription factor, termed Stat-SF, closely related to Stat3. I1:6 in SFs is important for Stat-SF activation, and is necessary, but not sufficient, for induction of Fc3/RI expression. This in vitro cell system can be used to further characterize the activated phenotype and to explore the molecular mechanism of monocyte activation by a complex inflammatory stimulus.
Materials and Methods
Monocyte Isolation and Culture. Mononuclear cells from diseasefree volunteers were obtained from whole blood or buffy coats (New York Blood Center, New York) by density gradient centrifugation using Ficoll metrizoate (Lymphoprep; GIBCO BRL, Gaithersburg, MD; endotoxin <0.25 endotoxin units [EU]/ml). Monocytes were further purified utilizing an aggregation method (25) that minimizes activation. Briefly, monocytes were aggregated for 45 min at 4~ at a monocyte density of 3.5-4.5 x 106/ml (estimated by myeloperoxidase staining) and purified by unit gravity sedimentation through fetal bovine serum (FBS) (Hyclone; endotoxin <0.06 EU/ml). Cell aggregates were disrupted and platelets completely removed by two washes with HBSS/1 mM EDTA and cells were cultured adherently on plastic dishes (Coming Inc., Coming, NY) in complete medium (AIM V medium; [GIBCO BRL; endotoxin <0.6 EU/ml] supplemented with 10% heat-inactivated human serum). IFN-'r (Genzyme Corp., Cambridge, MA; endotoxin <0.1 ng//~g) was added to purified monocytes immediately before plating. Neutralizing goat anti-IFN-% anti-Ib6, anti-TGF-/3, anti-IL-10 IgG, control goat IgG, and a mAb against Ib-6 were purchased from R&D Systems Inc., Minneapolis, MN. Pilot experiments demonstrated that these antisera neutralized exogenously added cytokines both in the absence or presence of SF.
Serum sources included autologous serum, a serum bank set up locally, and AB serum (GIBCO BRL) and gave similar results. Monocytes were >90% pure as assayed by cell surface expression of CD14 or the CD32 epitope recognized by mAb IV.3 (Medarex, New Lebanon, NH). In some experiments, monocytes were further purified to >97% purity (no CD3-positive cells detectable by flow cytometry) by removing additional T and B cells using magnetic beads (Dynal, Inc., Great Neck, NY) and gave similar results. Lack of monocyte activation during isolation was confirmed by lack of induction of IL-1 mRNA as measured by Northern analysis and RT-PCR. The total number of monocyte donors tested was greater than 40. The results obtained with different donors were qualitatively similar, even though the magnitude of induction varied. Throughout all experimental procedures, a scrupulous effort was made to avoid endotoxin contamination, including purchasing reagents that had been tested for endotoxin (GIBCO BRL; Hyclone Labs, Logan, UT; Genzyme Corp.), minimizing the use of glassware (and baking all glassware used at 190~ for 4 h), and by use of a water source (Millipore Corp., Bedford, MA) that contained <0.06 EU/ml of endotoxin as measured by the E-TOXATE Limulus amebocyte lysate assay (Sigma Chemical Co., St. Louis, MO).
SFs. SFs were obtained from patients with definite and classic R.A, as defined by the American College of Rheumatology criteria, by the patients' physicians for medically indicated reasons. Fluids were handled using sterile technique, centrifuged for 10 rain at lO,O00g to remove cells and particulate debris, aliquoted, and stored at -80~ In some experiments, SFs faltered through a 22-/~m filter were used and gave similar results. SFs were added to purified monocytes before plating.
Flow Cytometric Analysis. ELISA. The IFN-3,-specific ELISA was used according to the instructions of the manufacturer (Biosource International). SF samples were reduced and alkylated as described (15, 32) to inactivate RF. Pilot experiments showed that pretreatment of SFs with hyaluronidase (4) did not significantly affect detection of IFN-y. The standard curves of IFN-"/were generated using serial dilutions of IFN-'y (Genzyme Corp; sp act, 2.5 x 107 U/rag) diluted in SF or 10% normal human serum (15) and were similar. The standard samples were reduced and alkylated in the same manner as the SF samples. Reduction and alkylation did not significantly affect the measurement of IFN-3,.
Nuclear and Cellular Extract Preparation.
A nuclear mini-extract procedure (33) was used with modifications. 7 x 106 monocytes were washed in HBSS, resuspended, and incubated in buffer A (10 mM Hepes, 10 mM KC1, 1.5 mM MgC12, 1 mM dithiothreitol (DTT), 1 mM Pefablock SC (Boehringer Mannheim) and 20/zg/ml of aprotinin, leupeptin, antipain, and pepstatin A) for 10 min at 4~ NP-40 was added to a final concentration of 1% and after a 1-min incubation, nuclei were pelleted in a microcentrifuge, washed in buffer A, and lysed in 20/~1 of buffer C (10 mM Hepes, 420 mM KC1, 1.5 mM MgC12, 1 mM DTT, and the same protease inhibitors as buffer A). After 20 min of incubation at 4~ insoluble chromatin was pelleted by centrifugation, and the supernatant was aliquoted and stored at -80~ Total cell extracts were prepared by lysis in buffer containing 20 mM Hepes (pH 7.0), 300 mM NaC1, 10 mM KC1, 1 mM MgC12, 0.1% Triton X-100, 0.5 mM DTT, 200/~M PMSF, and 20% glycerol as described (24) . The protein concentration of extracts was determined using the Bradford assay.
DNA Binding and Gel Shift Assays. 3/xg of nuclear extract or 8 #g of cell extract was incubated with 0.2 or 0.5 ng of 32P-labeled, double-stranded oligonucleotide probe as described (34) , except that incubation was for 15 min on ice in a 10-/~1 reaction containing 80 mM KC1 and 2 #g of poly-dI-dC (Pharmacia, Piscataway, NJ) (nuclear extracts) and a 15-#1 reaction containing 100 mM NaC1 and 1/~g of poly-dI-dC (cell extracts). In competition experiments, an excess of unlabeled competitor oligonucleotide was incubated for 5 min with the nuclear extract before addition of labeled probe. Oligonucleotide sequences are: Ly-6E GAS, 5' CATGTTATGCATA-TTCCTGTAAGTG (35) ; hSIE, 5' GTCGACATTTCCCGTAA ATCGTCGA (24); GRR, 5' AGCATGTTTCAAGGATTTGAGA-TGTATTTCCCAGAAAAG (36); mutant GRtL, 5' AGCATGTTT-CAAGGATTTGAGA_~TATGGACCAGACAAG (STAT binding sites are underlined; mutated bases are in italics). In supershift experiments, 1/zl of a 1:10 dilution of specific antiserum (24) was added to extracts for 15 min before adding radiolabeled probe. Samples were resolved on 4 or 5% polyacrylamide gels in 0.25 x TBE buffer at 11 V/cm at room temperature. Gels were dried and subjected to autoradiography.
Results

SF Increase Cell Surface Expression of FcTRI, HLA DR, and Fc'yRIII (CD16).
We screened a panel of SFs for the ability to induce cell surface expression of the monocyte activation markers Fc'yRI, HLA DR, and Fc'yRIII (CD16). The results of a representative flow cytometry experiment are shown in Fig. 1 . SF1, derived from an RA patient, significantly increased cell surface expression of all three activation makers. The induction of Fc'yRI and HLA DR expression was comparable with that seen with 100 U/ml (4 ng/ml) of IFN-% A neutralizing anti-IFN-'y antibody prevented induction by IFN-3' (Fig. 1 , A and C), but not by SF1 (Fig. 1, B and D). The slight inhibition of SF induction of FcyRI ( Fig. 1  B) by anti-IFN-y antibody was not detected consistently. These results suggest SF-triggered induction of Fc3'RI and HLA DR expression is mediated by a factor(s) other than IFN-'y. SF1 triggered a dramatic induction of Fc3'RIII expression ( Fig. 1 E) , consistent with previous work which has attributed this effect to the presence of TGF-B (11).
In these experiments, both control and SF-and cytokinetreated monocytes were plated and allowed to adhere simultaneously with exposure to the soluble stimuli. This approach mimics the in vivo situation, where monocytes migrate into an inflamed joint and adhere to a connective tissue substrate as they become exposed to the inflammatory environment. Although, consistent with other reports (19, 20) , adherence induced expression of los, Ibl, and activation of NF-rB, it did not affect expression of FcyRI, Fc3'RIII, or HLA DR when compared to freshly isolated monocytes, or monocytes cultured nonadherently in TEFLON dishes (data not shown). Table 1 summarizes the results of screening 22 RA SFs. We chose to initially focus upon R.A SFs because RA is a relatively specific diagnosis and joint inflammation in RA has been studied extensively (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . 17 out of the 22 RA SFs tested induced expression of Fc3'RIII, confirming results obtained in a different system that used nonadherent culture of monocytes (11) . Greater than 80% of the RA SFs tested induced Fc'yRI and HLA DR expression, and most SFs induced all three activation markers. The major known inducer of both Fcq~RI and HLA DR is IFN-3'. However, since experiments with neutralizing antibodies against IFN-3, did not prevent induction by SFs ( Fig. 1 ; data not shown), other agents present in the fluid may be responsible. The induction of the markers we have examined does not appear to be specific to RA, since our limited survey of SFs obtained from patients with osteoarthritis (OA) or chronic traumatic effusions (Table  1) , and seronegative arthritis (data not shown), showed in- Fluids obtained from patients with RA, OA, and traumatic effusions were tested using flow cytometry for induction of monocyte cell surface expression of Fc3,RI, Fc"/RIII, and HLA DR. The numerator depicts the number of fluids that induced expression; the denominator, the total number of fluids tested. Positive induction was defined as a greater than twofold increase in mean cell surface fluorescence (Fc')'RI and FcyRIII) and an increase comparable with that induced by 100 U/ml (4 ng/ml) IFN-3'
(HLA DR).
* Chronic effusions secondary to mechanical injury which required arthroscopy.
duction of these markers. Both OA (37) We determined the effect of SF treatment on Fc'yRI, Fc3,RIII, and HLA D R A m R N A levels using Northern hybridization analysis (Fig. 2) . All eight SFs selected on the basis of induction of cell surface expression of Fc3,RI also induced Fc3'RI m R N A levels, and all eight fluid induced m R N A levels of the CD16 subunit of Fc3,RIII. The induction of HLA D R A m R N A expression was much less dramatic (Fig. 2) , consistent with a high baseline level of expression and the lower induction detected by flow cytometry. However, laser densitometry and comparison to levels of the GAPDH housekeeping gene showed that six out of the eight fluids tested increased HLA D R A m R N A levels to a degree comparable to the twofold induction seen with 100 U/ml (4 ng/ml) IFN-y (Fig. 2, lane 10) . 2-9) , or 100 U/ml (4 ng/ml) IFN-3' (lane 10) and cultured for 24 h. 5 /~g of total cellular RNA was fractionated on an agarose formaldehyde gel, transferred to a nylon membrane, and hybridized with radiolabeled cDNA probes.
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Sengupta et al. shown) suggested that this induction was not triggered by IFN-T. This conclusion is supported by results showing that the neutralizing anti-IFN-'y antibody also inhibited the induction of FcTRI mRNA levels by IFN-T, but not by SF1 or SF6 (Fig. 4) , or by two other SFs that were tested (data not shown).
To address the issue of the presence of IFN-T in the SFs more directly, we assayed IFN-T levels using both an ELISA and a sensitive bioassay. Table 2 shows that IFN-T was not detectable in 21 out of 22 RA SFs using an ELISA that can detect 200 pg/ml IFN-% and the remaining one fluid had a low level of IFN-% between 200 and 400 pg/ml. This would correspond to an IFN-3, concentration of 40-80 pg/ml final concentration in our cultures, where we used 20% SF, and is much lower than the levels of IFN-T (4 ng/ml), that were needed for induction of FcTRI, comparable with that seen with the SFs. We also used a bioassay that measures the actiration of DNA-binding by transcription factor Statl by IFN-'y. Within minutes of treatment of cells with IFN-T, Statl becomes phosphorylated and acquires specific DNA-binding activity (38) . Monocytes were cultured with IFN-3' or SFs, nuclear extracts were prepared, and the activation of Statl was assayed using gel shift assays with a radiolabeled Ly-6E promoter oligonucleotide probe that preferentially binds Statl compared with other STAT family members (21, 35) . Fig.  5 , lane 3, shows that 10 U/ml (400 pg/ml) IFN-y induced Statl DNA-binding activity. This DNA-binding activity was specific, since the shifted band was not detected in the presence of a 50-fold excess of unlabeled competitor oligonucleotide (Figs. 5, lane 2) . None of the eight SFs tested induced Statl DNA-binding activity (Fig. 5, lanes 4-11 ) . Since recent experiments with Statl mutant cell lines have demonstrated that Statl activation is necessary for IFN-'y responses of a wide spectrum of genes (39), our results strongly suggest that SF-triggered gene induction does not employ the IFN-'y signal transduction pathway.
Inflammatory SFs Activate a Stat3-related Transcription Factor that Binds Specifically to an Fcg/RI Promoter Sequence.
We performed gel shift assays using a radiolabeled high affinity serum inducible element (hSIE) oligonucleotide probe, which binds several STAT proteins and complexes (24, 40) . This approach allowed us to determine if SFs activated DNA-binding of STAT transcription factors other than Statl. Fig. 6 A shows that SFs induced an hSIE DNA-binding complex, which we have provisionally designated Stat-SF (lanes 3-10) , and which has a distinct mobility from the Star1 homodimer (41) IFN-y levels were measured using an ELISA with a sensitivity of 200 pg/ml (equivalent to 5 U/ml). 50-fold excess of the G R R effectively competed for Statl binding (Fig. 7, lanes 8-10) , but a 200-800-fold excess of the G R R was required to achieve a comparable level of competition for Stat-SF binding (Fig. 7, lanes 1-4) . A mutant G R R , m G R R , containing four base substitutions within the G R R STAT site, did not compete for Stat-SF binding even when present in 800-fold excess (Fig. 7, lanes 6 and 7) . Taken together, these results show that Stat-SF binds specifically to the G R R STAT site, but with a lower affinity than Star1. We used specific antisera generated against Star1 or Stat3 (24) to investigate whether Stat-SF was antigenically related duced formation of a DNA-protein complex that migrated similar to the migration of the Stat-SF complex in Fig. 6  (data not shown) . The binding of Stat-SF proteins to the hSIE was specific, because it was not affected by a 50-fold excess of unlabeled NF-gB oligonucleotide, but was abolished by a 50-fold excess of unlabeled hSIE (Fig. 6 B) . Fig. 6 B shows a representative experiment; the specificity of DNAbinding of the Stat-SF complex induced by five different SFs has been tested.
The Fc3~RI promoter contains a sequence, termed the IFN-'y response region (GRR), that mediates induction by IFN-% contains a STAT binding site TTCCCAGAA, and is known to bind Statl (36, 42, 43) . We used a 39-bp G R R oligonucleotide (36) as a competitor in gel shift assays to compare the binding of Statl and Stat-SF to the GR.R (Fig. 7) . A
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Sengupta et al. Figure 8 . Reactivity of Stat-SF with specific anti-STAT antisera. Cellular extracts (8 #g) from monocytes treated for 15 rain with SFs or IFN-3, were incubated with 1/zl of a 1:10 dilution of specific antisera generated against Statl or Stat3 (24) for 15 min before adding radiolabeled hSIE probe. DNA-protein complexes were resolved on 5 % nondenaturating polyacrylamide gels. FCTRI Figure 9 . StatlactivationbylFN-"(inthepresenceofSFs. Purifiedmonocytes were incubated for 15 min, and 8 #g of cellular extract was incubated with 0.5 ng of radiolabeled hSIE oligonucleotide. IFN-3, was used at 100 or 10 U/ml. Lanes 5-8 contained the same extract, which was preincubated with specific antisera against Statl or Star3.
to these proteins. Statl homodimer binding to the hSIE was completely abolished by the Statl, but not the Stat3, antiserum (Fig. 8, lanes I-3) . Stat-SF binding, in contrast, was abolished by Stat3 antiserum, and was affected only slightly by the Statl antiserum (Fig. 8, lanes 4-9; results from a representative experiment are shown). These results show that the predominant STAT protein induced by SFs is distinct from Statl, which is induced by IFN-y. The combination of Stat-SF DNA-binding specificity and mobility in gel shift assays, and its reactivity with the specific antisera, suggest strongly that Stat-SF contains Stat3 or a very dosely related STAT family member.
Role for 11-,6, but not IFN-% in Activation of Stat-SF and FcTRL
The difference in mobility between Stat-SF and IFNy-induced Statl (Fig. 6 A) allowed us to address directly whether we could detect IFN-7 bioactivity in the presence of SFs. Fig. 9 shows that addition of exogenous IFN-7 to SF, at concentrations of 100 or 10 U/ml, resulted in the activation of an additional DNA-binding complex with the mobility of Statl. Supershift experiments with anti-Statl and anti-Stat3 antibodies showed that the predominant DNAbinding complex in cells treated with both SF and IFN-7 contained Statl (Fig. 9, lanes 6-8) . Thus, SF did not mask IFN-7 bioactivity, and we would readily have detected the presence of IFN-7 in the SFs using this assay. A major activator of Stat3 is IL-6, a cytokine that is present in most SFs (1, 5) . Therefore, we tested whether neutralization of ILo6 in SFs would affect the activation of Stat-SF and the expression of FcyRI. Fig. 10 shows a representative experiment demonstrating that neutralization of IIr but not TGF-3, IL-10, or IFN-7, resulted in the complete inhibition of Stat-SF activation. The effect of neutralization was observed with both a specific anti-IL-6 antiserum and a mAb that has been tested extensively for lack of cross-reactivity with other cytokines. These antibodies effectively neutralized exogenous IL-6, as determined by the prevention of the activation of SIF-A, an IL-6-activated DNA-binding complex which contains Stat3 (24) , and which has a mobility similar to Stat-SF (Fig. 10, lanes 10-12) . These results show that IL-6 plays a major role in SF activation of Stat-SF, most likely through the activation of Stat3. (lane I0) (24) .
We used flow cytometry to determine whether inhibition of Stat-SF activation correlated with inhibition of FcTR.I expression. Fig. 11 shows that neutralization of IL-6, which inhibited Stat-SF activation (Fig. 10) , also dramatically inhibited the induction of FcTR.I expression. This inhibition also occurred at the level of Fc3,R`I mR.NA (data not shown). On the other hand, neutralizing antibody to IFN-T or IIA0 had no effect upon SF induction of Fc3,R.I expression (Fig:  11) . Interestingly, addition of IL-6 alone had minimal effect upon Fc'yRI expression, consistent with previous reports (44) . Our data show that IL-6 and Stat-SF activation are necessary but not sufficient for SF induction of FcTR.I, and suggest that a second signal, in addition to IL-6, is required.
Discussion
Monocytes make an important contribution to synovial inflammation in rheumatoid arthritis. Understanding how monocytes are activated in the inflamed joint would provide useful information about the pathogenesis of disease and also about the monocytic cell activation program. We have modeled the activation of monocytes which enter the inflamed joint by adhering resting monocytes in the presence of inflammatory SF. This approach makes possible an analysis of monocyte activation by a complex inflammatory stimulus, similar to activation in vivo. We have used this model to demonstrate SF induction of monocyte effector genes, address the issue of whether IFN-T plays an important role in monocyte activation in the inflamed joint, and show that SFs activate a signal transduction pathway that uses specific members of the STAT family of transcription factors.
Fc'yRI, FcyRIII, and HLA DR. are expressed at high levels in activated monocytes and in inflamed SF cells and synovial tissue (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Monocytes which enter an inflamed joint encounter numerous potentially activating stimuli, including (a) adherence to the extracellular matrix; (b) cell-cell interactions with synoviocytes and lymphocytes; and (c) exposure to soluble pro-inflammatory stimuli. Our results show that adherence plus the soluble factors in SF are sufficient to activate monocyte expression of FcTR.I, Fc"/R.III, and HLA DR., and likely activate a complex monocyte activation program. Adherence alone has been shown to activate NF-KB/rel family transcription factors and induce expression of cytokines such as IL-1 and TNF-oe (20) , findings which we have reproduced in our system (Ivashkiv, L., unpublished data). Adherence alone did not activate expression of FcyRI, Fc"yR.III, and HLA DR (Ivashkiv, L., unpublished data), but activation signals triggered by adherence likely affect the functional phenotype of the monocytes. Therefore, we carried out our analysis of the mechanism of monocyte activation by soluble pro-inflammatory stimuli in a system where both control and SF-and cytokine-stimulated monocytes were allowed to adhere as they were exposed to the soluble stimulus. This approach has the advantage of reproducing the simultaneous exposure to an inflammatory environment and adherence that occurs in vivo.
The issue of whether IFN-3' plays a role in activating monocytes in inflammatory synovitis has been controversial (1-4, 6, 9, 13, 14) . Our experiments provide three independent lines of evidence that the induction of FcTRI and HLA DR in our system is not dependent upon IFN-T. SF levels of IFN-T were very low or undetectable when measured by ELISA, consistent with the findings of other investigators (4). In addition, neutralizing antibodies to IFN-3' did not inhibit the ability of SFs to induce cell surface and mRNA expression of Fc3,RI and HLA DR., and SFs did not activate transcription factor Statl, which is necessary for gene activation by IFN-T (39). Furthermore, SFs did not mask the presence of IFN-% since we readily detected IFN-3, that was added to SFs both by ELISA (Ivashkiv, L., unpublished data), and by activation of Statl (Fig. 9) . Taken together, these findings demonstrate that monocyte activation by SFs does not depend upon IFN-3', and strongly argue that monocyte activation in inflammatory disease can occur in the absence of IFN-T.
Treatment of monocytes with SFs induced a specific DNAbinding activity, which we have provisionally designated Stat-SF, within 15 min of stimulation. This DNA-binding protein bound to oligonucleotides containing a STAT binding site, but not to an irrelevant NF-KB oligonucleotide or a mutant oligonucleotide with four base substitutions within the STAT site. In contrast to IFN-T-induced Statl, Stat-SF binding activity was neutralized by a specific antiserum directed against Stat3, but not by an antiserum against Statl. Stat-SF also had a mobility in a gel shift assay which was distinct from that of Statl (Fig. 6) . A tyrosine-phosphorylated protein which migrated with the mobility of Stat3 was immunoprecipitated from SF-treated monocytes by the Stat3 antiserum (Sengupta, T., and Z. Zhong, unpublished data). Based upon these criteria, we believe that Stat-SF contains Stat3 or a very closely related member of the STAT family.
We have determined that the SF factor which plays a predominant role in activation of Stat-SF is IL-6. IL-6 is a proinflammatory cytokine present in a majority of SFs (1, 5) , and activates DNA-binding of the SIF-A complex, which contains Stat3. SIF-A has been proposed to be a homodimer of Stat3, although the presence of additional proteins has not been ruled out (21, 24) . The similarity of the mobility of SIF-A and Stat-SF (Fig. 10) , and their common activation by Ib6 suggest that these complexes may be closely related or identical. However, different DNA-binding complexes often comigrate on the nondenaturing gels used in these assays. Thus, differences in the identity or posttranslational modification of proteins which associate with Stat3 to form SIF-A or Stat-SF could have escaped detection in our experiments. The relationship between Stat-SF and SIF-A can be investigated by a biochemical analysis of purified proteins.
Our data with neutralizing antibodies showed that TGF-/3, II~10, and IFN-y, are not necessary for Stat-SF activation. Other cytokines, however, may play an important role, possibly by regulating proteins that associate with Stat3 in the Stat-SF complex. An interesting issue is why we did not detect activation of STATs by other cytokines present in SFs, especially cytokines, such as LIF, oncostatin M (OsM), IL-10, and PDGF, which activate Stat3 (24, 40, (45) (46) (47) . This lack of cytokine activity cannot be completely explained by the absence of the cytokine from a specific SF, limitations of the gel shift assays, or lack of monocyte receptors for a factor such as PDGF (Sengupta, T., unpublished data). It will be interesting to explore whether SFs can suppress monocyte responses to particular cytokines, possibly by uncoupling signal transduction pathways.
Interestingly, neutralization of ILo6 and inhibition of Stat-SF activation resulted in the inhibition of the induction of Fc'yRI expression. Stat-SF binds specifically, albeit with relatively low affinity, to the GRR, an inducible transcription element present in the Fc3,RI promoter (36) . Thus, Stat-SF may regulate Fc'yRI expression directly through binding to the GRR, but an indirect mechanism of regulation is also possible. The presence of IL-6 in SFs is necessary, but not sufficient to activate Fc3'RI expression, since treatment of monocytes with purified II,-6 had minimal effect upon FcyRI expression. Treatment with IL-6, however, did activate the SIF-A complex, which has a similar mobility to Stat-SF. Our data suggest that the SFs are providing a second signal that synergizes with the I1:6 signal. An interesting possibility is that the second signal modifies the SIF-A complex, possibly by changing the identity of the proteins that make up the complex, or by altering posttranslational modifications.
STAT proteins are triggered by numerous cytokines to activate transcription of many cellular genes leading to major changes in cell phenotype. Our system provides an opportunity to systematically study the activation of STAT proteins and physiologically relevant target effector genes which are activated by inflammatory SF, and to determine which factors present in SF are important for activation. This will yield a greater understanding of monocyte activation by complex inflammatory stimuli in vivo, and should provide insight into pathogenetic mechanisms in inflammatory arthritis.
